Biogena Group Invest AG (WBO:BIO) Research & Development: €0.00 Mil (TTM As of Jan. 2026)


WBO:BIO Biogena Group Invest AG WBO:BIO
65 GF Score
Price €4.08
GF Value €3.45
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biogena Group Invest AG Research & Development?

Biogena Group Invest AG WBO:BIO +11.48% 65 Research & Development is €0.00 Mil as of Jan. 2026. GuruFocus rates WBO:BIO with a GF Score™ of 65/100 and a GF Value™ of €3.45 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Biogena Group Invest AG's Research & Development for the six months ended in Jan. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 was €0.00 Mil.

Biogena Group Invest AG  (WBO:BIO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Biogena Group Invest AG Research & Development Related Terms

Biogena Group Invest AG Research & Development Historical Data

* Premium members only.

The historical data trend for Biogena Group Invest AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogena Group Invest AG Research & Development Chart

Biogena Group Invest AG Annual Data
Trend Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Biogena Group Invest AG Semi-Annual Data
Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
WBO:BIO
65GF Score
Biogena Group Invest AG WBO:BIO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogena Group Invest AG Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Biogena Group Invest AG (WBO:BIO) has a Research & Development of €0.00 Mil as of Jan. 2026. Research and development expense is the total cost for research and development activities. View historical data on Biogena Group Invest AG and its competitors.
Is Biogena Group Invest AG's Research & Development too high?
Biogena Group Invest AG's current Research & Development is €0.00 Mil. Overall, Biogena Group Invest AG has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's Research & Development compare to KHC and GIS?
Biogena Group Invest AG's Research & Development of €0.00 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Biogena Group Invest AG and its competitors. Biogena Group Invest AG's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.45, compared to a current price of €4.08 — trading 18.3% above its estimated fair value. The current Research & Development is €0.00 Mil. Biogena Group Invest AG's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current Research & Development is €0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued. The current stock price of €4.08 is trading 18.3% above its estimated GF Value™ of €3.45. GuruFocus considers Biogena Group Invest AG to be Modestly Overvalued.

Key valuation signals for WBO:BIO:

  • Research & Development: €0.00 Mil
  • GF Value™: €3.45 vs. price of €4.08 (18.3% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogena Group Invest AG Business Description

Address Strubergasse 24, Salzburg, AUT, 5020
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
65GF Score

Get the complete analysis for WBO:BIO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€3.45
GF Value